FRONTAGE HOLDINGS CORPORATION
方達控股公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1521)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 7, 2026

> **POLL RESULTS OF THE EGM**
>
> The Board is pleased to announce that the resolution proposed at the EGM held on January 7, 2026 were duly passed by way of poll.

POLL RESULTS OF THE EGM

The board (the "**Board**") of directors (the "**Directors**") of Frontage Holdings Corporation (the "**Company**") is pleased to announce the voting results of the extraordinary general meeting of the Company (the "**EGM**") held on Wednesday, January 7, 2026. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the circular of the Company dated December 15, 2025 (the "**Circular**").

The resolution proposed at the EGM was taken by poll. The Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As at the date of the EGM, the total number of issued Shares was 2,035,724,910 Shares (including 3,536,000 Shares which have been repurchased and were yet to be cancelled). As stated in the Circular, Hangzhou Tigermed and Hongkong Tigermed, directly holding 226,020,000 Shares and 1,088,484,090 Shares, respectively, abstained from voting at the EGM on the resolution proposed at the EGM. As such holders of 717,684,820 Shares were entitled to attend and vote for or against the resolution proposed at the EGM. The Company does not have any treasury shares (as defined under the Listing Rules).

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholders had indicated in the Circular that they intended to vote against the resolution at the EGM.

The poll results in respect of the resolution proposed at the EGM are as follows:

Ordinary Resolution		Number of Votes (%)	
		For	**Against**
1.	THAT (a) the share transfer agreement (the "**Share Transfer Agreement**") dated October 10, 2025 entered into by Frontage Laboratories (Shanghai) Co., Ltd.* (方達醫藥技術(上海)有限公司), Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格醫藥科技股份有限公司) and Jiaxing Xinge Medical Consulting Co., Ltd.* (嘉興欣格醫藥科技有限公司) and the proposed transactions and other matters contemplated thereunder, be and are hereby confirmed, approved and ratified; and (b) any one of the directors of the Company be and is hereby authorized to do all such acts and things incidental to the Share Transfer Agreement and the relevant ancillary agreements as he/she considers necessary, desirable or expedient in connection with the implementation of or giving effect to the Share Transfer Agreement, the relevant ancillary agreements and the transactions contemplated thereunder.	262,472,853 (100.00%)	0 (0.00%)

\#   *The full text of the resolution above is set out in the notice of the EGM dated December 15, 2025.*

As more than 50% of the votes were cast in favour of the resolution above, the resolution was duly passed as an ordinary resolution of the Company by way of poll at the EGM.

All Directors attended the EGM in person or by electronic means.

By Order of the Board
Frontage Holdings Corporation
Dr. Song Li
Chairman

Hong Kong, January 7, 2026

As of the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive Directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive Directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors.

* *For identification purposes only*